Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Boostrix

National Institutes of Health

Related topics

Related topics

8 relations

Broader (8)

Bordetella pertussis filamentous hemagglutinin vaccine, inactivatedBordetella pertussis pertactin vaccine, inactivatedBordetella pertussis toxoid vaccine, inactivatedDiphtheria-Tetanus-(whole-cell) Pertussis Vaccine
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand.
BACKGROUND We estimated the vaccine effectiveness (VE) of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Review
2012
Review
2012
Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®)
SummaryAbstractBoostrix® is a three-pertussis component, combined, reduced-antigen content tetanus, diphtheria, and acellular… Expand
  • table I
  • table II
  • table III
  • table IV
  • figure 1
2011
2011
Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.
BACKGROUND Older adults, especially those over 65 years, are at risk of more severe morbidity from diphtheria, tetanus and… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 4
2011
2011
FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
  • MMWR. Morbidity and mortality weekly report
  • 2011
    • Corpus ID: 21322585
On July 8, 2011, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced… Expand
2011
2011
[Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
  • Y. Ma, Min Qin, +7 authors Ming Sun
  • Zhonghua shi yan he lin chuang bing du xue za zhi…
  • 2011
    • Corpus ID: 1602266
OBJECTIVE In order to search the preparation process and optimazing dosage ratio of adsorbed diphtheria-tetanus-acellular… Expand
2010
2010
Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™)
Pertussis continues to circulate in Chinese communities and older children, adolescents and adults are sources of infection for… Expand
Review
2009
Review
2009
Boostrix™: a reduced-dose acellular pertussis vaccine for use in adolescents and adults
Pertussis remains a serious problem in many countries. Even in countries with high vaccine coverage and a long vaccination… Expand
2009
2009
FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
  • MMWR. Morbidity and mortality weekly report
  • 2009
    • Corpus ID: 30102812
On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced… Expand
2005
2005
Boostrix (GlaxoSmithKline).
  • T. Jones
  • IDrugs : the investigational drugs journal
  • 2005
    • Corpus ID: 25236141
GlaxoSmithKline plc has developed and launched Boostrix, a subunit vaccine for use in adolescents and adults as a booster… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE